Replimune Group, Inc. reported a net loss of $70.9 million for the third quarter of fiscal 2026, an increase from the $66.34 million loss recorded in the same quarter a year earlier. The widening loss reflects higher research and development and selling, general, and administrative expenses that support ongoing clinical trials and preparations for a potential commercial launch of its lead product candidate, RP1.
The company also announced a revised loan agreement with Hercules Capital, Inc. that provides an immediate $35 million draw and reserves an additional $120 million to be accessed after regulatory milestones. The amendment pushes the start of debt amortization to October 1 2027, extending Replimune’s cash runway into the first quarter of 2027 and giving the company breathing room to fund commercial readiness activities for RP1.
Replimune’s BLA resubmission for RP1 was accepted by the FDA in October 2025, with a Prescription Drug User Fee Act target action date of April 10 2026. CEO Sushil Patel emphasized the significance of the milestone, noting that RP1 combined with nivolumab offers a strong risk‑benefit profile for patients who have progressed on PD‑1 therapy and that the company is working closely with the agency to expedite the review process.
Commercial readiness is progressing, with manufacturing inventory already built and a 60‑person sales team trained to engage target accounts. The company is also advancing its supply‑chain, marketing, and market‑access strategies to support a potential launch of RP1 once regulatory approval is obtained.
Analysts have assigned a “Hold” rating to the stock, with consensus earnings estimates for the quarter at a negative $0.64 per share. While the company’s earnings miss reflects continued cash burn, the combination of an extended cash runway, a favorable regulatory timeline, and a growing commercial pipeline provides a foundation for future upside as the company moves closer to product launch.
Investors remain focused on the company’s ability to convert its clinical progress into commercial revenue, weighing the extended runway against the ongoing investment in R&D and commercialization. The April 10 PDUFA deadline remains a critical inflection point for Replimune’s trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.